Surgical prioritization based on decision model outcomes is not sensitive to differences between the health-related quality of life values estimates of physicians and citizens

Figures

• 

  Fig. 1. Bland–Altman plots of the HRQoL values from CP1 and CP2 (upper) and all citizens (CP) and physicians (PP) (lower). All plots are stratified for the pre-operative (left) and post-operative (right) health states. Mean A = 0.02, mean B = 0.05, mean C = − 0.05, and mean D = − 0.10. The y-axis shows the mean difference in HRQoL values and the x-axis represents the average of the HRQoL values based on data from two respondent panels. Each dot represents a vignette. The dashed horizontal lines represent the Bland–Altman bias and 95% limits of agreement

• 

  Fig. 2. HRQoL values estimated by the citizens and physicians, stratified for the pre-operative (left) and post-operative (right) health state. AVR aortic valve replacement, ESLD end-stage liver disease, ESRD end-stage renal disease, HCC hepatocellular cancer, PAD F3-4 peripheral arterial disease Fontaine 3–4, TAVI transcatheter aortic valve, VATS video-assisted thoracoscopy

• 

  Fig. 3. Model outcome established using HRQoL values from physicians (left) and all citizens (right). The average DALYs per month of surgical delay are displayed. The estimates (grey bars) and 95% confidence intervals (black lines) are shown. AVR aortic valve replacement, ESLD end-stage liver disease, ESRD end-stage renal disease, HCC hepatocellular cancer, PAD F3-4 peripheral arterial disease Fontaine 3–4, TAVI transcatheter aortic valve, VATS video-assisted thoracoscopy

• 

  Fig. 4. Ranking of surgeries established using HRQoL values from physicians (left) and all citizens (right). The grey horizontal lines represent no shift in ranking position due to using citizens’ HRQoL values compared with physicians’ HRQoL values. The orange lines represent a drop in position, whereas the blue lines show an increase. AVR aortic valve replacement, ESLD end-stage liver disease, ESRD end-stage renal disease, HCC hepatocellular cancer, PAD F3-4 peripheral arterial disease Fontaine 3–4, TAVI transcatheter aortic valve, VATS video-assisted thoracoscopy